Comparison · NCT03474107-784140ed
Enfortumab Vedotin 1.25 mg/kg vs Chemotherapy: Number of Participants With Treatment Emergent Adverse Events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Enfortumab Vedotin 1.25 mg/kg vs Chemotherapy: Number of Participants With Treatment Emergent Adverse Events. Trial comparisons, record NCT03474107-784140ed. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03474107-784140ed
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.98 | 0.956 | 0.991 | wilson | |
| Risk in group 2 | 0.99 | 0.97 | 0.996 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00996 | -0.0342 | 0.0125 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.99 | 0.97 | 1.01 | log | |
| Odds ratio, group 1 over group 2 | 0.503 | 0.125 | 2.03 | log | |
| Number needed to treat, for one fewer participant with the outcome on Enfortumab Vedotin 1.25 mg/kg than on Chemotherapy | 100 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Enfortumab Vedotin 1.25 mg/kg | Participants received 1.25 mg/kg of body weight enfortumab vedotin by IV infusion over approximately 30 minutes on days 1, 8 and 15 of every 28-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first. | 290 | 296 | OG000 |
| Group 2 | Chemotherapy | Participants received either 75 mg/m\^2 docetaxel by IV infusion over approximately 1 hour or 320 mg/m\^2 vinflunine by IV infusion over approximately 20 minutes or 175 mg/m\^2 paclitaxel by IV infusion over approximately 3 hours on day 1 of every 21-day cycle. Participants received study treatment until radiological disease progression as determined per investigator assessment or other discontinuation criteria were met or upon study termination, or study completion, whichever occurred first. | 288 | 291 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment Emergent Adverse Events
- Description
An AE is any untoward medical occurrence in a participant temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. A TEAE is defined as an AE observed or worsened after starting administration of the study drug.
- Time frame
- From first dose up to 30 days after last dose (Median (range) time on study drug was 4.99 (0.5, 19.4) months in enfortumab vedotin and 3.45 (0.2, 15.0) months in chemotherapy group)
- Population
- The safety analysis set (SAF) consisted of all participants who received any amount of study drug, and was used for safety analyses.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- NCT number
- NCT03474107
- Phases
- PHASE3
- Conditions
- Ureteral Cancer, Urothelial Cancer, Bladder Cancer
- Interventions
- Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Results first posted
- 2021-08-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03474107?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03474107-784140ed